Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001013594-25-001417
Filing Date
2025-11-14
Accepted
2025-11-14 10:54:43
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 12385
  Complete submission text file 0001013594-25-001417.txt   14322
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Subject) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-45969 | Film No.: 251482642
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 22 FIELDVIEW LANE SUITE 108 EAST HAMPTON NJ 11937
Business Address 22 FIELDVIEW LANE SUITE 108 EAST HAMPTON NJ 11937 917-923-7400
Contrarian Alpha, LP (Filed by) CIK: 0001921222 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A